18-F flornaptitril - CereMark Pharma
Alternative Names: [F-18]FDDNP; F-18-flornaptitril; F-18-FNT; F-18-FNT-PET; FDDNPLatest Information Update: 22 Mar 2024
At a glance
- Originator University of California at Los Angeles
- Developer CereMark Pharma
- Class Diagnostic agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Alzheimer's disease; Brain disorders
Most Recent Events
- 12 Feb 2024 Phase-II clinical trials in Alzheimer's disease (Diagnosis) (unspecified route) prior to February 2024 (CereMark Pharma pipeline, February 2024)
- 12 Feb 2024 Phase-II clinical trials in Brain disorders (Diagnosis) (unspecified route) prior to February 2024 (CereMark Pharma pipeline, February 2024)
- 12 Feb 2024 CereMark Pharma plans a phase III trial for Alzheimer dsease and Chronic traumatic encephalopathy in unknown location (NCT06254469)